Login to Your Account

FDA Unveils Plan for Structured Benefit-Risk Assessment

By Mari Serebrov
Washington Editor

Friday, March 8, 2013
Seeking to lift the veil on its approval process, the FDA released a draft five-year plan describing the steps it's taking to further develop and implement a structured benefit-risk assessment to be used in agency reviews of drugs and biologics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription